Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Status:
Terminated
Trial end date:
2015-07-31
Target enrollment:
Participant gender:
Summary
A Phase I/II clinical trial using a fractionated dosing regimen of 90Y-epratuzumab
(anti-CD22) has showed encouraging responses in follicular and aggressive NHL with an ability
to administer safely 2 injections of 20 mCi/m2 spaced 1 week apart. The investigators propose
to combine this active 90Y-epratuzumab treatment with a regimen of veltuzumab that was also
found active in Phase I/II trials.
The goal of this study is to determine the safety and efficacy of 90Y-epratuzumab when used
in combination with veltuzumab. The primary objective is to determine the response rate of
this combination treatment. Secondary objectives are to assess safety, pharmacokinetics and
targeting of 90Y-epratuzumab . Veltuzumab blood levels and anti-antibody responses will also
be monitored at various times.